Evaluation of Gastrografin Therapeutic Role in the Management of Small Bowel Obstruction


Sina Safamanesh 1 , Abdolreza Pazouki 1 , Zeinab Tamannaie 1 , * , Behnoush Mohammadalipour 2 , Koosha Ramezani 1 , Esmaeel Hajnasrollah 3 , Ghazal Hajnasrollah 3 , Shahla Chaichian 4

1 Minimally Invasive Surgery Research Center, Tehran University of Medical Sciences, [email protected], IR Iran

2 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, IR Iran

3 Department of Surgery, Shahid Beheshti University of Medical Sciences, IR Iran

4 Faculty of Medicine, Islamic Azad University, Tehran Medical Branch, IR Iran

How to Cite: Safamanesh S, Pazouki A, Tamannaie Z, Mohammadalipour B, Ramezani K, et al. Evaluation of Gastrografin Therapeutic Role in the Management of Small Bowel Obstruction, J Minim Invasive Surg Sci. Online ahead of Print ; 2(1):90-3.


Journal of Minimally Invasive Surgical Sciences: 2 (1); 90-3
Published Online: February 28, 2013
Article Type: Research Article
Received: June 27, 2012
Accepted: August 13, 2012


Background: Small bowel obstruction is one of the most common surgical emergencies and main causes of hospital admissions. Diatrizoate Meglumine Gastrografin, a hyperosmolar water-soluble contrast agent, has been used to triage patients with small bowel obstruction for an operative or a non-operative management. It can also have a therapeutic effect by increasing the pressure gradient across obstructive sites that may result in resolving the obstruction.

Objectives: The aim of this study was to test the gastrografin effect in the resolution of small bowel obstruction.

Patients and Methods: In this cross sectionaldescriptive study, gastrografin was given to patients diagnosed with small bowel obstruction in clinical and radiological grounds . The contrast passage was assessed by serial X-rays. If the contrast remained in the small bowel, a decision was made as to whether proceed to surgical intervention, based on clinical condition. The patients were divided into two groups: A, who finally required surgery, and B, who were resolved by gastrografin administration.

Results: Forty six patients were entered into the study. Thirty seven of the patients (80%) received a non-operative course in whom the contrast was observed in the large bowel. They had a mean hospital stay of 4.6 days. Nine patients (20%) required operative intervention. These patients had a mean hospital stay of 8 days.

Conclusions: This study has demonstrated that gastrografin was highly effective in the management of adhesive small bowel obstruction resulting in a decreased need for surgery and hospital stay.

Full Text

Full text is available in PDF

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.